DelveInsight’s “Von Willebrand Disease (VWD) Market Insights, Epidemiology, and Market Forecast 2032″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Von Willebrand Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Von Willebrand Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Von Willebrand Disease (VWD): An Overview
Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types according to inheritance or acquired forms.
The specific symptoms and severity of VWD can vary greatly from one person to another, even among individuals with the same subtype or members of the same family. Some individuals may not develop symptoms until adulthood; others may be affected during infancy. Most individuals have a mild form of the disorder.
Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.
Von Willebrand Disease (VWD)Market Key Facts
According to DelveInsight analysis, the total diagnosed prevalent population of VWD in seven major markets was 33,000+ in 2017.
Among the 7MM, the highest diagnosed prevalence of VWD is estimated in the United States, with 11,000+ diagnosed cases in 2017.
The lowest prevalent population of VWD was recorded in Japan among the 7MM.
Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.
According to a review article published by Masato Nishino titled “Consensus Diagnosis and Treatment of von Willebrand Disease,” the number in Japan has increased gradually up to 735 cases (0.56 per 105 persons), possibly, in parallel with the extent of concern about VWD.
Von Willebrand Disease (VWD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Von Willebrand Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Von Willebrand Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Von Willebrand Disease (VWD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Von Willebrand Disease (VWD) Epidemiology, Segmented as –
Total Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2019–2032)
Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2019–2032)
Type-Specific Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2019–2032)
Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2019–2032)
Von Willebrand Disease (VWD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Von Willebrand Disease market or expected to be launched during the study period. The analysis covers the Von Willebrand Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Von Willebrand Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Von Willebrand Disease Market Will Evolve and Grow by 2032 @
Von Willebrand Disease (VWD) Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Von Willebrand’s Disease. Currently, Band Therapeutics is leading the therapeutics market with its Von Willebrand’s Disease drug candidates in the most advanced stage of clinical development.
Leading Companies in the Von Willebrand Disease Therapeutics Market Include:
China Biologic Products
Grifols Biological Inc.
And Many Others
Von Willebrand’s Disease Emerging and Marketed Drugs Covered in the Report Include:
Alphanate: Grifols Biological Inc.
BT200: Band Therapeutics
Desmopressin: Ferring Pharmaceuticals
Fanhdi: Grifols Biological Inc.
Humate-P/Haemate P: CSL Behring
Voncento: CSL- Behring
Wilfactin/Wilfact: LFB Biomedicaments
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Von Willebrand Disease Competitive Intelligence Analysis
4. Von Willebrand Disease Market Overview at a Glance
5. Von Willebrand Disease Disease Background and Overview
6. Von Willebrand Disease Patient Journey
7. Von Willebrand Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Von Willebrand Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Von Willebrand Disease Unmet Needs
10. Key Endpoints of Von Willebrand Disease Treatment
11. Von Willebrand Disease Marketed Products
12. Von Willebrand Disease Emerging Drugs and Latest Therapeutic Advances
13. Von Willebrand Disease Seven Major Market Analysis
14. Attribute Analysis
15. Von Willebrand Disease Market Outlook (In US, EU5, and Japan)
16. Von Willebrand Disease Access and Reimbursement Overview
17. KOL Views on the Von Willebrand Disease Market
18. Von Willebrand Disease Market Drivers
19. Von Willebrand Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States